Anti-Human CD52 Antibody (SAA0023), PE

Catalog No.

FHD95112

Species reactivity

Human

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

PE

Target

Human epididymis-specific protein 5, CDW52, CAMPATH-1 antigen, Cambridge pathology 1 antigen, He5, HE5, Epididymal secretory protein E5, CD52, CDw52

Concentration

0.5 mg/ml

Endotoxin level

Please contact with the lab for this information.

Accession

P31358

Applications

FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.

Stability and Storage

Store at 4°C for 12 months. Protect from light. Do not freeze.

Clone ID

SAA0023

Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: definition of different patient archetypes from an Italian expert group perspective., PMID:40481170

Clinical management of alemtuzumab-induced autoimmune thyroid diseases: a narrative review., PMID:40440332

Targeting EBV-infected T cells with alemtuzumab: a novel approach to systemic chronic active EBV disease., PMID:40304862

Alemtuzumab for haematological malignancies., PMID:40214729

Real-world safety and effectiveness of alemtuzumab for relapsed or refractory chronic lymphocytic leukaemia: results from postmarketing surveillance in Japan., PMID:40156871

T-cell prolymphocytic leukemia, a case report and review of the literature., PMID:40109866

Immuno-oncological Challenges and Chemoresistance in Veterinary Medicine: Probiotics as a New Strategic Tool., PMID:39954194

Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies., PMID:39946666

Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study., PMID:39916320

Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas., PMID:39899393

Alemtuzumab and thrombotic thrombocytopenic purpura: Analysis of an international surveillance database and systematic literature review., PMID:39883995

Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates., PMID:39693508

Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients?, PMID:39655586

Multi-omic characteristics of longitudinal immune profiling after breakthrough infections caused by Omicron BA.5 sublineages., PMID:39536392

Methotrexate, Hydrocortisone, Vincristine, Sobuzoxane, and Etoposide Is an Effective Option for Relapsed T-cell Prolymphocytic Leukemia with Loss of CD52 Expression after Retreatment with Alemtuzumab., PMID:39513061

SCALA: a randomized phase I trial comparing subcutaneous and intravenous alemtuzumab in patients with progressive multiple sclerosis., PMID:39513023

Identification of alemtuzumab-suitable multiple sclerosis patients in Slovakia and sequencing of post-alemtuzumab immunomodulatory treatment., PMID:39494112

Alemtuzumab-induced thyroid disease: A Danish cohort study., PMID:39293122

Cis-interaction between CD52 and T cell receptor complex interferes with CD4+ T cell activation in acute decompensation of cirrhosis., PMID:39276679

Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis., PMID:39251561

Acute Coronary Syndrome as an Unusual Initial Presentation of T-Prolymphocytic Leukemia: A Case Report and Review of the Literature., PMID:39228413

Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series., PMID:39151236

Cryptococcosis Associated With Biologic Therapy: A Narrative Review., PMID:38947739

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses., PMID:38941598

Flow Cytometry as an Alternative to Microscopy for the Differentiation of BAL Fluid Leukocytes., PMID:38548099

Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab., PMID:38471303

Alemtuzumab infusion-associated reactions and laboratory changes in patients with relapsing-remitting multiple sclerosis at baseline and first-year follow-up., PMID:38444472

Evaluation of the paired-Cas9 nickase and RNA-guided FokI genome editing tools in precise integration of an anti-CD52 bicistronic monoclonal antibody expression construct at Chinese hamster ovary cells 18S rDNA locus., PMID:38342386

The role of graft T-cell size in patients receiving alemtuzumab serotherapy for non-malignant disorders: results of an institutional protocol., PMID:38200046

Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis., PMID:38181696

Maintenance therapy for chronic lymphocytic leukaemia., PMID:38174814

Hematopoietic stem cell transplantation for B-thalassemia major with alemtuzumab., PMID:38131101

Alemtuzumab-induced immune-mediated thrombotic thrombocytopenic purpura: A newly described drug-related autoimmune disease., PMID:38112161

Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas., PMID:37998391

[Chronic neutrophilic leukemia/chronic eosinophilic leukemia]., PMID:37914248

Delayed Diagnosis of T-Cell Prolymphocytic Leukemia: Approach to Chronic Lymphocytosis., PMID:37900812

Novel miRNA-based drug CD5-2 reduces liver tumor growth in diethylnitrosamine-treated mice by normalizing tumor vasculature and altering immune infiltrate., PMID:37795103

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety., PMID:37782084

Tumor Lysis Syndrome with CD20 Monoclonal Antibodies for Chronic Lymphocytic Leukemia: Signals from the FDA Adverse Event Reporting System., PMID:37755660

Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control., PMID:37744364

The Contribution of Multiplexing Single Cell RNA Sequencing in Acute Myeloid Leukemia., PMID:37489448

[Alemtuzumab-induced Graves' disease]., PMID:37448247

Overexpression of SIRT6 alleviates apoptosis and enhances cell viability and monoclonal antibody expression in CHO-K1 cells., PMID:37286776

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study., PMID:37285798

Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis., PMID:37149155

Targeted Large-Volume Lymphocyte Removal Using Magnetic Nanoparticles in Blood Samples of Patients with Chronic Lymphocytic Leukemia: A Proof-of-Concept Study., PMID:37108680

Alemtuzumab treatment exemplifies discordant immune effects of blood and cerebrospinal fluid in multiple sclerosis., PMID:37062182

A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience., PMID:37054581

An unforeseen reality: Hemophagocytic lymphohistiocytosis following alemtuzumab treatment for a multiple sclerosis., PMID:36965418

Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence., PMID:36902555

Document Download

Anti-Human CD52 Antibody (SAA0023), PE.pdf